30 closest matches · ranked by relevance
Behçet's Syndrome
Primary: Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12) — 222.14; 129.54 Ulcers*days — p=<0.0001
Autoimmune Connective Tissue Disorder · Immune System Diseases
Primary: Clinical Remission From Months 3-6 — 2 Participants
Behcet Syndrome
Primary: Number of Oral Ulcers at Day 85 — 2.0; 0.4 ulcers/participants — p=<0.0001
Behcet's Disease · Behcet Syndrome · Neuro-Behcet's Disease
Primary: Percentage of Participants With Complete Response at Week 30 — 54.5; 0; 100; 100 percentage of Complete Responders
Behcet Disease
Primary: Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment — 7.7; 11.5; 7.7 Ocular Exacerbations
Behcet Syndrome · Behcet Disease · Mucocutaneous Ulceration
Primary: Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm. — 13; 10; 12 patients with sustained response — p=0.404
Behcet Disease
Primary: Number of Participants With Attacks — 0 Participants
Behcet's Disease
Primary: Number of Participants With Adverse Drug Reactions — 47; 5; 6; 1 Participants
Intestinal Behçet's Disease
Primary: Number of Participants With Marked Improvement at Week 24 — 9 participants
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Chronic Beryllium Disease
Primary: Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6 — 48.61; 9.33; 22.07; 3.8 Stimulation index
Uveitis
Primary: Number of Participants Experiencing a Treatment Response by Week 16 — 4; 2 Participants
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Takayasu's Arteritis · Giant Cell Arteritis
Primary: Primary Outcome - Relapse-free Survival (RFS) — 10; 14; 8; 10 Participants — p=0.049
Ulcerative Colitis
Primary: Percentage of Participants Achieving Endoscopic Improvement — 16.7 percentage of participants
Ankylosing Spondylitis
Primary: Occurence Rate of Uveitis Attacks in Participants Before Anti-TNF/GLM Treatment and After the Start of GLM Treatment — 0.08; 0.08 Ratio — p=1.0000
Crohn's Disease
Primary: Remission at Week 26 — 61; 37 Participants — p=0.0048
Ulcerative Colitis
Primary: Proportion of Patients Who After Study Completion Achieve Clinical Response Defined by at Least a 3point Decrease & 30% Reduction From Baseline in Mayo Score Plus ≥ 1…
Known Crohn Disease Subjects
Primary: Mucosal Change in VCE (Video Capsule Endoscopy) Mucosal Scores and PGA (Physician Global Assessment) — -0.3; -382.9; -2.7 units on a scale — p=0.631
Pyoderma Gangrenosum · Crohn's Disease · Ulcerative Colitis
Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 26.1; 59.5; 57.3 Percentage of…
Psoriasis
Primary: Change in Histology
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
Pemphigus
Primary: Participant Response to Treatment at Week 18 — 1; 1 Participants — p=1.00
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Castleman Disease · Multicentric Castleman Disease · Giant Lymph Node Hyperplasia
Primary: Percentage of Participants With an Overall Clinical Benefit Response — 63; 100; 50; 67 percentage of participants